New Imaging Procedure for the Localisation of Insulinoma
Status
Conditions
Treatments
Details and patient eligibility
About
Insulinoma: Insulinoma are rare, small insulin secreting neuroendocrine tumors. The only curative approach is the surgical excision. The preoperative detection remains a challenge. A non-invasive, highly sensitive tool in localizing the insulinomas would be appreciated in the preoperative work-up of these patients. To this aim Glucagon-like peptide-1 receptor (GLP-1R) imaging (Single Photon Emission Computer Tomography co-registered with a CT; SPECT/CT) could be a convenient tool. The possibly more sensitive approach of targeting GLP-1R using Positron emission tomography (PET/CT) methodology has not been investigated in patients so far.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Biochemically proven endogenous hyperinsulinaemic hypoglycaemia in the fasting state with neuroglycopenic symptoms or autologous Islet Cell transplantation in the forearm
- Conventional imaging (CT,MRI or EUS) not older than 2 months
- Signed written consent
- Age above 18 years
Exclusion criteria
- Kidney failure (creatinine > 140micromol/l)
- Known allergies against Exendin-4 (Byetta or Bydureon)
- Pregnancy
- Breastfeeding
- Medication with Byetta or Bydureon
- Evidence for malignancy (extrapancreatic tumor manifestations)
Trial design
Primary purpose
Allocation
Interventional model
Masking
52 participants in 1 patient group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal